Trial Site Detail
Drug: |
QINLOCK
Ripretinib
DCC-2618 |
|||
|---|---|---|---|---|
Trial: |
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Active, not recruiting |
|||
Dana Farber Cancer Institute450 Brookline Ave |
Principal Investigator: |
George Demetri, MD |
|---|---|
Contact: |
Tarsha Huftalen, RN, BSN 617-632-5117 tmhuftalen@partners.org |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Dana Farber Cancer Institute Website: |
http://www.dana-farber.org/Research/Clinical-Trials.aspx |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.